1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1N-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR Russian patent published in 2020 - IPC C07D403/12 A61K31/506 A61P25/28 A61P29/00 A61P19/04 A61P35/00 A61P13/10 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a novel compound—1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea of formula I or its dihydrochloride salt. Compounds have the properties of a selective TrkA kinase inhibitor and can be used to treat a disease or disorders selected from a group consisting of pain, cancer, inflammation or inflammatory diseases, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases associated with bone tissue remodeling imbalance, as well as diseases caused by aberrant transmission of connective tissue growth factor signals. Novel compound corresponds to formula I

and can be obtained by reacting a compound of formula II-A with compound III, or IV, or VII

with removal of protective groups, in case of their presence, and optionally obtaining a dihydrochloride salt of compound I. Either the compound of formula I can be obtained by reacting compound V or VI

with compound III, and removing protective groups, if any, and optionally obtaining the dihydrochloride salt of compound I. Reaction conditions and values of radicals are given in the claim.

EFFECT: compound of formula I and its dihydrochloride salt have considerably higher activity indices when used in comparison with closest analogues and are intended for oral administration.

27 cl, 4 dwg, 13 tbl, 9 ex